The FDA Approved the First Cholesterol Pill of Its Kind Before Its Trial Could Show It Prevents Heart Attacks or Deaths

In a trial called CORALreef Outcomes, 14,550 people at high risk of a heart attack take a pill every morning. Half are swallowing Merck’s new cholesterol drug, half a placebo, and none of them know yet which group is doing better. The trial does not reach its primary finish line until November 29, 2029. Only then will anyone know whether the drug prevents heart attacks, strokes, and cardiac deaths, or merely lowers a number on a lab report.

The drug went on sale years ahead of the answer.

In mid-July the Food and Drug Administration approved Lipfendra, Merck’s enlicitide, as the first oral PCSK9 inhibitor cleared in the United States. The class itself is old news. Injectable PCSK9 inhibitors, the kind you keep in the refrigerator and inject every two to four weeks, have been on pharmacy shelves for roughly a decade. What is new is the form factor: a once-daily tablet that hits the same target the needles do. Swapping a refrigerated shot for a pill you take with breakfast is the kind of convenience that decides whether people stay on a drug at all, and that is worth saying plainly before saying anything else.

So look at what the approval actually rests on. In the head-to-head CORALreef trial published in the Journal of the American College of Cardiology, enlicitide cut LDL cholesterol by 64.6 percent from baseline over eight weeks, against 27.8 percent for ezetimibe, 6.3 percent for bempedoic acid, and 36.5 percent for the two older pills combined. In the broader CORALreef program, it lowered LDL by a placebo-adjusted 59 percent in patients with an inherited form of high cholesterol and 56 percent in adults with ordinary hypercholesterolemia. The number moves, and it moves hard. That is the clinical-efficacy basis for the approval.

Notice what is not in those figures. Not one number about heart attacks, strokes, or deaths, because there isn’t one. The FDA cleared Lipfendra on a laboratory value, the concentration of LDL in a blood draw, and not on any evidence that lowering that value with this particular molecule keeps a single patient out of the cardiac ward. LDL is what regulators call a surrogate endpoint, a stand-in for the outcome that actually matters to the person taking the drug. The pill lowers the number. It has not been shown to save a life.

To be fair to the surrogate, LDL is one of the better ones in medicine. Statins lower it and were made to prove, in large outcomes trials, that they cut cardiac events. The injectable PCSK9 inhibitors lowered it and in time ran their own outcomes studies, which showed the drop bought a modest reduction in heart attacks and strokes. The link between LDL and cardiovascular disease is about as solid as anything in cardiology. Merck’s bet is not reckless.

But it is a bet, and the history of lipid drugs is full of reasons to collect the winnings before spending them. Torcetrapib raised HDL, the “good” cholesterol, beautifully, and when Pfizer finally ran the 15,067-patient outcomes trial, the drug turned out to raise the risk of death, a hazard ratio of 1.58 with a 95 percent confidence interval of 1.14 to 2.19. The company shut the program down in a matter of days. That is why the large trial exists, and why “it improved the blood work” is the beginning of the argument and not the end of it. Merck enrolled its 14,550 patients precisely to measure major adverse cardiovascular events, the composite of cardiac death, heart attack, and stroke. The trial has finished enrolling. It has not finished counting.

What changes now, concretely, is the checkout line. Merck set the list price at about $315 a month, or roughly $3,800 a year, and is pitching it as a bargain against the $500 to $600 monthly tab on the injectables. RBC Capital Markets projects the pill could bring in around $5 billion a year by 2034. AstraZeneca, whose own oral PCSK9 candidate posted an 80 percent LDL reduction when stacked on a statin in an early trial, got beaten to the shelf and is years behind. A convenient pill that lowers a frightening number, priced under the incumbents, aimed at one of the largest patient populations in the country: that is a commercial win regardless of what the outcomes trial eventually reports.

For the patient with dangerously high cholesterol who cannot tolerate a statin, or the person with an inherited condition whose LDL will not come down any other way, a potent once-daily tablet is worth having, and their doctors will have good reason to reach for it. The honest description is just narrower than the marketing: what Lipfendra is proven to do is lower LDL cholesterol, emphatically, and what it is not yet proven to do is anything a patient can feel or a family can be spared.

Merck will spend the next three years collecting roughly $3,800 a year per patient on the strength of a lab value, while the trial that would tell us whether the value was worth chasing keeps its answer sealed until the end of 2029.

Sources

1. FDA – Approval of Lipfendra (enlicitide), first oral PCSK9 inhibitor (July 2026)
2. ClinicalTrials.gov – CORALreef Outcomes cardiovascular MACE trial, NCT06008756 (14,550 participants, 1:1 randomization, primary completion Nov 29, 2029)
3. Journal of the American College of Cardiology – Catapano et al., enlicitide vs oral nonstatin therapies, phase 3 CORALreef AddOn (2026)
4. BioSpace – Merck’s first FDA approval for an oral PCSK9 inhibitor: LDL figures, price, and peak-sales estimate
5. NEJM (ILLUMINATE) – Barter et al., effects of torcetrapib in patients at high risk for coronary events (2007)
6. Circulation – Vega et al., laroprovstat (AZD0780), AstraZeneca’s oral small-molecule PCSK9 inhibitor, phase 1 (2026)